drugset / Trial / NCT00554099

Asacol Acute Diverticulitis(DIVA)Study

NCT00554099

Phase 2 Completed 117 enrolled Warner Chilcott
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to determine whether Asacol® 2.4 g/day (400 mg Mesalamine) is safe and effective in the treatment of diverticulitis.

Timeline

Start
2007-11
Primary completion
2010-03
Completion
2010-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator Bifidobacterium infantis 35624 Other / unclassified
Comparator Mesalamine Small molecule 400 mg

Indications